ImClone Systems, Inc.
http://www.imclone.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ImClone Systems, Inc.
Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
Chinese Language Podcast: 创新药美国获批, AI新药研发, 三季度业绩和中美峰会
Topics in this latest Chinese-language podcast include the US approval of Chinese innovative drugs including Junshi’s anti-PD-1 antibody toripalimab, Sanofi’s deal with BioMap for AI-powered drug discovery, Chinese companies' third-quarter results and the Biden-Xi summit on the sidelines of APEC and its implications for bilateral regulatory dialog.
Slashed Activities, Reduced Sales: Commercial Crackdown Dents Drug Makers In China
Among multinationals, AstraZeneca has reported its commercial activities have been negatively impacted by China's broad anti-corruption campaign, while J&J has seen some affect from the country's volume-based procurement scheme. Roche, Lilly and Novartis have also reported some softness in the last quarter versus the previous three months.
Hasten Joins China's PCSK9 Race With In-Licensing, Commercialization Capabilities
Chinese firm Hasten has gained greater China rights to LIB Therapeutics’ lerodalcibep for hypercholesterolemia and believes its bet on the unique PCSK9-binding small protein will be backed by strong commercialization capability, the company says in an interview with Scrip.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice